(19)
(11) EP 4 388 079 A1

(12)

(43) Date of publication:
26.06.2024 Bulletin 2024/26

(21) Application number: 23700385.0

(22) Date of filing: 02.01.2023
(51) International Patent Classification (IPC): 
C12N 1/20(2006.01)
C12R 1/145(2006.01)
 C12N 9/52(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 1/20; C12R 2001/145; C12N 9/52
(86) International application number:
PCT/EP2023/050027
(87) International publication number:
WO 2023/131588 (13.07.2023 Gazette 2023/28)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 05.01.2022 EP 22150333
30.08.2022 DE 102022121862

(71) Applicant: Nordmark Pharma GmbH
25436 Uetersen (DE)

(72) Inventors:
  • HEYLAND, Jan
    25436 Uetersen (DE)
  • STAWORZYNSKA-GÖDDE, Malgorzata
    25436 Uetersen (DE)
  • SCHRÄDER, Thomas
    25436 Uetersen (DE)

(74) Representative: RGTH 
Patentanwälte PartGmbB Neuer Wall 10
20354 Hamburg
20354 Hamburg (DE)

   


(54) CULTURE MEDIUM FOR CULTIVATING HATHEWAYA HISTOLYTICA (OR CLOSTRIDIUM HISTOLYTICUM) AND THE PRODUCTION OF ONE OR MORE PROTEASES